Eun Young Chae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eun Young Chae has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Hak Hee Kim
Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
26 shared publications - Hee Jung Shin
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
24 shared publications - Joo Hee Cha
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea
23 shared publications - Woo Jung Choi
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
16 shared publications Woo Jung Choi
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
9 shared publicationsJoo Hee Cha
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
8 shared publications
Latest Publications
- 2 April 2026
- Published by Springer Nature in European Radiology
- Vol. 36 (8) , 6682-6696
Long-term prognostic implications of AI-detected versus AI-undetected breast cancers on mammography: a propensity score-matched analysis
Objectives To evaluate the association between the cancer detectability by artificial intelligence (AI) and long-term survival outcomes in invasive breast cancer. Materials and methods This retrospective study analyzed consecutive women diagnosed with invasive breast cancer who underwent preoperative mammography between January and December 2013. Mammograms were analyzed using FDA-cleared AI software (Lunit INSIGHT MMG v1.1.8.2). Cancers were classified as AI-detected if correctly localized by AI, and AI-undetected if AI missed or mislocalized. Propensity score matching was performed using 29 clinical, pathological, and treatment-related covariates. Recurrence-free survival (RFS) and overall survival (OS) were compared using Kaplan–Meier estimates and Cox proportional hazards models. Results Among 879 women (mean age ± standard deviation, 50.3 ± 10.2 years), AI correctly identified cancers in 83%. Before matching, the AI-detected group had higher recurrence (11% vs 5%; p = 0.02) and mortality rates (7% vs 1%; p = 0.003). Distant recurrence was also more prevalent in AI-detected cases (p = 0.04). After matching, no differences were observed in RFS (HR, 1.7 [95% CI: 0.8, 3.9]; p = 0.20) or OS (HR, 4.1 [95% CI: 0.5, 38.1]; p = 0.21). AI detectability was not associated with RFS (HR, 1.9 [95% CI: 0.9, 3.8]; p = 0.07) or OS (HR, 5.5 [95% CI: 0.8, 40.7]; p = 0.09) in multivariable analysis. Conclusion AI-detected breast cancers showed higher recurrence and mortality rates in the unadjusted analysis. However, after adjusting for confounders, AI detectability was not associated with RFS or OS, suggesting that AI may preferentially detect tumors with aggressive characteristics. Key Points Question AI-based software for mammography interpretation is increasingly being integrated into practice, but the long-term prognostic implications of breast cancers detected or undetected by AI remain unclear. Findings In this retrospective study, AI detectability was not associated with recurrence-free (HR, 1.7; p = 0.20) or overall survival (HR, 4.1; p = 0.21) after propensity score matching. Clinical relevance AI may be more likely to detect biologically aggressive tumors, rather than directly influencing survival. Graphical Abstract
- 2 April 2026
- Published by Springer Nature in European Radiology
- Vol. 36 (8) , 6682-6696
Long-term prognostic implications of AI-detected versus AI-undetected breast cancers on mammography: a propensity score-matched analysis
Objectives To evaluate the association between the cancer detectability by artificial intelligence (AI) and long-term survival outcomes in invasive breast cancer. Materials and methods This retrospective study analyzed consecutive women diagnosed with invasive breast cancer who underwent preoperative mammography between January and December 2013. Mammograms were analyzed using FDA-cleared AI software (Lunit INSIGHT MMG v1.1.8.2). Cancers were classified as AI-detected if correctly localized by AI, and AI-undetected if AI missed or mislocalized. Propensity score matching was performed using 29 clinical, pathological, and treatment-related covariates. Recurrence-free survival (RFS) and overall survival (OS) were compared using Kaplan–Meier estimates and Cox proportional hazards models. Results Among 879 women (mean age ± standard deviation, 50.3 ± 10.2 years), AI correctly identified cancers in 83%. Before matching, the AI-detected group had higher recurrence (11% vs 5%; p = 0.02) and mortality rates (7% vs 1%; p = 0.003). Distant recurrence was also more prevalent in AI-detected cases (p = 0.04). After matching, no differences were observed in RFS (HR, 1.7 [95% CI: 0.8, 3.9]; p = 0.20) or OS (HR, 4.1 [95% CI: 0.5, 38.1]; p = 0.21). AI detectability was not associated with RFS (HR, 1.9 [95% CI: 0.9, 3.8]; p = 0.07) or OS (HR, 5.5 [95% CI: 0.8, 40.7]; p = 0.09) in multivariable analysis. Conclusion AI-detected breast cancers showed higher recurrence and mortality rates in the unadjusted analysis. However, after adjusting for confounders, AI detectability was not associated with RFS or OS, suggesting that AI may preferentially detect tumors with aggressive characteristics. Key Points Question AI-based software for mammography interpretation is increasingly being integrated into practice, but the long-term prognostic implications of breast cancers detected or undetected by AI remain unclear. Findings In this retrospective study, AI detectability was not associated with recurrence-free (HR, 1.7; p = 0.20) or overall survival (HR, 4.1; p = 0.21) after propensity score matching. Clinical relevance AI may be more likely to detect biologically aggressive tumors, rather than directly influencing survival. Graphical Abstract
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (3) , e250783
Interreader Agreement and Diagnostic Confidence in Discriminating Masses and Nonmass Lesions at Breast US
Interreader agreement for classifying lesions as either masses or nonmass lesions at breast US was moderate to substantial (κ = 0.534–0.638), indicating a high level of concordance.
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (3) , e250783
Interreader Agreement and Diagnostic Confidence in Discriminating Masses and Nonmass Lesions at Breast US
Interreader agreement for classifying lesions as either masses or nonmass lesions at breast US was moderate to substantial (κ = 0.534–0.638), indicating a high level of concordance.
- 1 September 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 316 (3) , e243823
Node Reporting and Data System Evaluation of Axillary Nodes in Invasive Ductal and Lobular Carcinoma
The Node Reporting and Data System score demonstrated comparable area under the receiver operating characteristic curve in axillary nodal evaluation for invasive ductal and lobular carcinoma but lower sensitivity for invasive lobular carcinoma.
- 1 September 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 316 (3) , e243823
Node Reporting and Data System Evaluation of Axillary Nodes in Invasive Ductal and Lobular Carcinoma
The Node Reporting and Data System score demonstrated comparable area under the receiver operating characteristic curve in axillary nodal evaluation for invasive ductal and lobular carcinoma but lower sensitivity for invasive lobular carcinoma.
- 26 July 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 191, 112340
Background parenchymal enhancement as a predictor of invasive disease-free survival in hormone receptor-positive, HER2-negative breast cancer
- 26 July 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 191, 112340
Background parenchymal enhancement as a predictor of invasive disease-free survival in hormone receptor-positive, HER2-negative breast cancer
- 1 April 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (1) , e242712
Impact of Preoperative MRI on Survival Outcomes in Patients with HER2-positive and Hormone Receptor–negative Breast Cancer
In women with human epidermal growth factor receptor 2—positive and hormone receptor–negative breast cancer, preoperative MRI was not associated with improved recurrence-free or overall survival.
- 1 April 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (1) , e242712
Impact of Preoperative MRI on Survival Outcomes in Patients with HER2-positive and Hormone Receptor–negative Breast Cancer
In women with human epidermal growth factor receptor 2—positive and hormone receptor–negative breast cancer, preoperative MRI was not associated with improved recurrence-free or overall survival.
- Open Access
- 1 January 2025
- Published by XMLink in Investigative Magnetic Resonance Imaging
- Vol. 29 (1) , 23-30
The Role of Preoperative Breast MRI in Patients With Early-Stage Breast Cancer
Choi WJ, et al. Investig Magn Reson Imaging. 2025 Mar;29(1):23-30. https://doi.org/10.13104/imri.2024.0025
- 1 January 2025
- Published by XMLink in Investigative Magnetic Resonance Imaging
- Vol. 29 (1) , 23-30
Open AccessThe Role of Preoperative Breast MRI in Patients With Early-Stage Breast Cancer
Choi WJ, et al. Investig Magn Reson Imaging. 2025 Mar;29(1):23-30. https://doi.org/10.13104/imri.2024.0025
- 8 July 2024
- Published by Elsevier in Physica Medica
- Vol. 124, 103419
Optimizing angular range in digital breast tomosynthesis: A phantom study investigating lesion detection across varied breast density and thickness
- 8 July 2024
- Published by Elsevier in Physica Medica
- Vol. 124, 103419
Optimizing angular range in digital breast tomosynthesis: A phantom study investigating lesion detection across varied breast density and thickness
- 24 May 2024
- Published by Springer Nature in European Radiology
- Vol. 34 (11) , 7092-7103
A predictive model using MRI and clinicopathologic features for breast cancer recurrence in young women treated with upfront surgery
To identify preoperative breast MR imaging and clinicopathological variables related to recurrence and develop a risk prediction model for recurrence in young women with breast cancer treated with upfront surgery. This retrospective study analyzed 438 consecutive women with breast cancer aged 35 years or younger between January 2007 and December 2016. Breast MR images before surgery were independently reviewed by breast radiologists blinded to patient outcomes. The clinicopathological data including patient demographics, clinical features, and tumor characteristics were reviewed. Univariate and multivariate logistic regression analyses were used to identify the independent factors associated with recurrence. The risk prediction model for recurrence was developed, and the discrimination and calibration abilities were assessed. Of 438 patients, 95 (21.7%) developed recurrence after a median follow-up of 65 months. Tumor size at MR imaging (HR = 1.158, p = 0.006), multifocal or multicentric disease (HR = 1.676, p = 0.017), and peritumoral edema on T2WI (HR = 2.166, p = 0.001) were identified as independent predictors of recurrence, while adjuvant endocrine therapy (HR = 0.624, p = 0.035) was inversely associated with recurrence. The prediction model showed good discrimination ability in predicting 5-year recurrence (C index, 0.707 in the development cohort; 0.686 in the validation cohort) and overall recurrence (C index, 0.699 in the development cohort; 0.678 in the validation cohort). The calibration plot demonstrated an excellent correlation (concordance correlation coefficient, 0.903). A prediction model based on breast MR imaging and clinicopathological features showed good discrimination to predict recurrence in young women with breast cancer treated with upfront surgery, which could contribute to individualized risk stratification. Our prediction model, incorporating preoperative breast MR imaging and clinicopathological features, predicts recurrence in young women with breast cancer undergoing upfront surgery, facilitating personalized risk stratification and informing tailored management strategies. Younger women with breast cancer have worse outcomes than those diagnosed at more typical ages. The described prediction model showed good discrimination performance in predicting 5-year and overall recurrence. Incorporating better risk stratification tools in this population may help improve outcomes.
- 24 May 2024
- Published by Springer Nature in European Radiology
- Vol. 34 (11) , 7092-7103
A predictive model using MRI and clinicopathologic features for breast cancer recurrence in young women treated with upfront surgery
To identify preoperative breast MR imaging and clinicopathological variables related to recurrence and develop a risk prediction model for recurrence in young women with breast cancer treated with upfront surgery. This retrospective study analyzed 438 consecutive women with breast cancer aged 35 years or younger between January 2007 and December 2016. Breast MR images before surgery were independently reviewed by breast radiologists blinded to patient outcomes. The clinicopathological data including patient demographics, clinical features, and tumor characteristics were reviewed. Univariate and multivariate logistic regression analyses were used to identify the independent factors associated with recurrence. The risk prediction model for recurrence was developed, and the discrimination and calibration abilities were assessed. Of 438 patients, 95 (21.7%) developed recurrence after a median follow-up of 65 months. Tumor size at MR imaging (HR = 1.158, p = 0.006), multifocal or multicentric disease (HR = 1.676, p = 0.017), and peritumoral edema on T2WI (HR = 2.166, p = 0.001) were identified as independent predictors of recurrence, while adjuvant endocrine therapy (HR = 0.624, p = 0.035) was inversely associated with recurrence. The prediction model showed good discrimination ability in predicting 5-year recurrence (C index, 0.707 in the development cohort; 0.686 in the validation cohort) and overall recurrence (C index, 0.699 in the development cohort; 0.678 in the validation cohort). The calibration plot demonstrated an excellent correlation (concordance correlation coefficient, 0.903). A prediction model based on breast MR imaging and clinicopathological features showed good discrimination to predict recurrence in young women with breast cancer treated with upfront surgery, which could contribute to individualized risk stratification. Our prediction model, incorporating preoperative breast MR imaging and clinicopathological features, predicts recurrence in young women with breast cancer undergoing upfront surgery, facilitating personalized risk stratification and informing tailored management strategies. Younger women with breast cancer have worse outcomes than those diagnosed at more typical ages. The described prediction model showed good discrimination performance in predicting 5-year and overall recurrence. Incorporating better risk stratification tools in this population may help improve outcomes.
- Open Access
- 1 January 2024
- Published by XMLink in Korean Journal of Radiology
- Vol. 25 (1) , 11-23
Unenhanced Breast MRI With Diffusion-Weighted Imaging for Breast Cancer Detection: Effects of Training on Performance and Agreement of Subspecialty Radiologists
Kim YS, et al. Korean J Radiol. 2024 Jan;25(1):11-23. https://doi.org/10.3348/kjr.2023.0528
- 1 January 2024
- Published by XMLink in Korean Journal of Radiology
- Vol. 25 (1) , 11-23
Open AccessUnenhanced Breast MRI With Diffusion-Weighted Imaging for Breast Cancer Detection: Effects of Training on Performance and Agreement of Subspecialty Radiologists
Kim YS, et al. Korean J Radiol. 2024 Jan;25(1):11-23. https://doi.org/10.3348/kjr.2023.0528
- Open Access
- 24 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (47) , e36301
Assessing internal mammary lymph node metastasis by breast magnetic resonance imaging in breast cancer
The internal mammary lymph nodes (IMLNs) are a main pathway of metastasis in breast cancer, and breast magnetic resonance imaging (MRI) plays an important role in staging that disease. We investigated the MRI parameters that can predict metastatic IMLNs and evaluated their diagnostic performance by comparing the breast MRI findings for metastatic and benign IMLNs. From January 2016 to December 2020, 474 cases of enlarged IMLNs on breast MRI were identified. By cytopathology or integrated positron emission tomography/computed tomography (PET/CT), 168 IMLNs were confirmed as metastatic, and 81 were confirmed as benign. Breast MRIs were reviewed by 2 radiologists, and various parameters (node axes, fatty hilum, necrosis, margin characteristics, restricted diffusion, and involved levels; primary tumor location and skin involvement) were assessed. Independent t-tests, receiver operating characteristic (ROC) curve analyses, chi-square tests, and Fisher exact tests were performed to compare and evaluate the diagnostic accuracy of the imaging findings. Significant differences in the breast MRI findings for the short and long axes, fatty hilum, necrosis, margin characteristics, diffusion restriction, and tumor location were observed between benign and metastatic IMLNs. Compared with the long axis and the ratio of the axes, the short axis had the best diagnostic value (higher area under the ROC curve) for predicting metastatic IMLNs. In conclusion, breast MRI parameters such as short axis, presence of fatty hilum, necrosis, margin characteristics, and diffusion restriction can be used to evaluate and differentiate benign from metastatic IMLNs, offering valuable insights to improve diagnosis and treatment planning in breast cancer.
- 24 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (47) , e36301
Open AccessAssessing internal mammary lymph node metastasis by breast magnetic resonance imaging in breast cancer
The internal mammary lymph nodes (IMLNs) are a main pathway of metastasis in breast cancer, and breast magnetic resonance imaging (MRI) plays an important role in staging that disease. We investigated the MRI parameters that can predict metastatic IMLNs and evaluated their diagnostic performance by comparing the breast MRI findings for metastatic and benign IMLNs. From January 2016 to December 2020, 474 cases of enlarged IMLNs on breast MRI were identified. By cytopathology or integrated positron emission tomography/computed tomography (PET/CT), 168 IMLNs were confirmed as metastatic, and 81 were confirmed as benign. Breast MRIs were reviewed by 2 radiologists, and various parameters (node axes, fatty hilum, necrosis, margin characteristics, restricted diffusion, and involved levels; primary tumor location and skin involvement) were assessed. Independent t-tests, receiver operating characteristic (ROC) curve analyses, chi-square tests, and Fisher exact tests were performed to compare and evaluate the diagnostic accuracy of the imaging findings. Significant differences in the breast MRI findings for the short and long axes, fatty hilum, necrosis, margin characteristics, diffusion restriction, and tumor location were observed between benign and metastatic IMLNs. Compared with the long axis and the ratio of the axes, the short axis had the best diagnostic value (higher area under the ROC curve) for predicting metastatic IMLNs. In conclusion, breast MRI parameters such as short axis, presence of fatty hilum, necrosis, margin characteristics, and diffusion restriction can be used to evaluate and differentiate benign from metastatic IMLNs, offering valuable insights to improve diagnosis and treatment planning in breast cancer.